Is curcumin bioavailability a problem in humans: lessons from clinical trials

Kunnumakkara, Ajaikumar B.; Harsha, Choudhary; Banik, Kishore; Vikkurthi, Rajesh; Sailo, Bethsebie Lalduhsaki; Bordoloi, Devivasha; Gupta, Subash C.; Aggarwal, Bharat B.

doi:10.1080/17425255.2019.1650914

Cited by 152 publications

(98 citation statements)

References 335 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…258 Further studies have confirmed the effects of curcumin on the Wnt/β-catenin and Hippo/YAP signaling pathways, inhibiting stemness or proliferation in multiple cancers. [259][260][261][262][263][264][265] Although limited bioavailability and stability hamper the application of curcumin in clinical cancer therapy, [266][267][268] curcumin has been used for treating patients with pancreatic cancer in clinical trials due to its anticancer activity and safety profile. 269,270 Drug repurposing of curcumin could prove beneficial for clinical translation using highly bioavailable forms of curcumin (e.g., micro-and nano-formulations of curcumin with greatly enhanced absorption) to target telomerase.…”

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

334

296

View full text Add to dashboard Cite

Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono-or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake.

show abstract

Section: Non-oncology Drugs In Drug Repurposingmentioning

confidence: 99%

Overcoming cancer therapeutic bottleneck by drug repurposing

Zhang

Zhou

Xie

et al. 2020

Sig Transduct Target Ther

334

296

View full text Add to dashboard Cite

show abstract

“…Curcumin clinical trials in different cancers are extensively done [ 135 ]. Clinical trials regarding curcumin treatment in bladder cancer demonstrated that 8000 mg/day of its dose for 3 months confer no side effects and has also attenuated bladder cancer lesions [ 136 ].…”

Section: Clinical Trials On Resveratrol Curcumin or Paclitaxel In Camentioning

confidence: 99%

Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) is a leading cause of death among urothelial malignancies that more commonly affect male population. Poor prognosis and resistance to chemotherapy are the two most important characteristics of this disease. PI3K/Akt/mTOR signaling pathway has been considered pivotal in the regulation of proliferation, migration, invasiveness, and metastasis. Deregulation of PI3K/Akt/mTOR signaling has been found in 40% of bladder cancers. Several microRNAs (miRNAs) have been reported to interact with the PI3K/Akt/mTOR signaling pathway with a different possible role in proliferation and apoptosis in bladder cancer. Thus, miRNAs can be used as potential biomarkers for BC. Natural compounds have been in the spotlight for the past decade due to their effective anti-proliferative capabilities. However, little is known of its possible effects in bladder cancer. The aim of this review is to discuss the interplay between PI3K/Akt/mTOR, miRNAs, and natural compounds and emphasize the importance of miRNAs as biomarkers and resveratrol, curcumin and paclitaxel as a possible therapeutic approach against bladder cancer.

show abstract

“…Curcumin was shown to have anticancer and chemopreventive potential in different types of cancers, as discussed in several reviews [112][113][114]. Its relative non-toxicity allowed to overcome any biovailability concers, resulting in over 200 clinical trials investigating the protective role of curcumin against cardiovascular, metabolic, neurological, inflammatory and many other diseases [115]. It affects a wide range of cancer-related pathways, including inflammation, oxidative stress, apoptosis, and others.…”

Section: Modulation Of Tumorigenic Pathways As a Chemoprevention Stramentioning

confidence: 99%

Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview

Ashraf-Uz-Zaman

Bhalerao

Mikelis

et al. 2020

Cancers

View full text Add to dashboard Cite

Chemoprevention of lung cancer is thought to significantly reduce the risk of acquiring these conditions in the subpopulation of patients with underlying health issues, such as chronic obstructive pulmonary disorder and smoking-associated lung problems. Many strategies have been tested in the previous decades, with very few translating to successful clinical trials in specific subpopulations of patients. In this review, we analyze these strategies, as well as new approaches that have emerged throughout the last few years, including synthetic lethality concept and microbiome-induced regulation of lung carcinogenesis. Overall, the continuous effort in the area of lung chemoprevention is required to develop practical therapeutical approaches. Given the inconsistency of results obtained in clinical trials targeting lung cancer chemoprevention in various subgroups of patients that differ in the underlying health condition, race, and gender, we believe that individualized approaches will have more promise than generalized treatments.

show abstract

Is curcumin bioavailability a problem in humans: lessons from clinical trials

Cited by 152 publications

References 335 publications

Overcoming cancer therapeutic bottleneck by drug repurposing

Overcoming cancer therapeutic bottleneck by drug repurposing

Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer

Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview

Contact Info

Product

Resources

About